ResearcherStony Brook UniversityActive in the last 2 years

Dillon Matthew Voss

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7481-9455; OpenAlex author ID A5043853373; NIH RePORTER profile ID 15572916. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 1
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2024: 1 paper · 2025: 1 grant · 2026: 1 paper

Papers 2

ASO-based PKM splice-switching therapy increases anti-CTLA-4 antibody efficacy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41421-026-00882-9 ↗
Screening Splice-Switching Antisense Oligonucleotides in Pancreas-Cancer Organoids. Co-author DOI 10.1089/nat.2023.0070 ↗

Grants 1

Inducing PKM splice-switching with antisense oligonucleotides as an approach to treat hepatocellular carcinoma F30CA271804 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Adrian R. Krainer · 2 shared papers, 2024–2026 · strength 0.51
- Paper ASO-based PKM splice-switching therapy increases anti-CTLA-4 antibody efficacy in pancreatic ductal adenocarcinoma. DOI 10.1038/s41421-026-00882-9 ↗
- Paper Screening Splice-Switching Antisense Oligonucleotides in Pancreas-Cancer Organoids. DOI 10.1089/nat.2023.0070 ↗
Lijie Han · 1 shared paper, 2026 · strength 0.28
- Paper ASO-based PKM splice-switching therapy increases anti-CTLA-4 antibody efficacy in pancreatic ductal adenocarcinoma. DOI 10.1038/s41421-026-00882-9 ↗
Hao Chen · 1 shared paper, 2026 · strength 0.28
- Paper ASO-based PKM splice-switching therapy increases anti-CTLA-4 antibody efficacy in pancreatic ductal adenocarcinoma. DOI 10.1038/s41421-026-00882-9 ↗
Ledong Wan · 1 shared paper, 2024 · strength 0.23
- Paper Screening Splice-Switching Antisense Oligonucleotides in Pancreas-Cancer Organoids. DOI 10.1089/nat.2023.0070 ↗
Alexander J. Kral · 1 shared paper, 2024 · strength 0.23
- Paper Screening Splice-Switching Antisense Oligonucleotides in Pancreas-Cancer Organoids. DOI 10.1089/nat.2023.0070 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.